Solventum (STU:KB7) Beginning Cash Position: €760 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:KB7 Solventum Corp STU:KB7
34 GF Score
Price €71.20
! 8 Warning Signs
View Full Analysis

What is Solventum Beginning Cash Position?

Solventum STU:KB7 +4.40% 34 Beginning Cash Position is €760 Mil as of Mar. 2026. GuruFocus rates STU:KB7 with a GF Score™ of 34/100. The stock has 8 warning signs investors should review.

Solventum's Beginning Cash Position for the quarter that ended in Mar. 2026 was €760 Mil.

Solventum's quarterly Beginning Cash Position increased from Sep. 2025 (€421 Mil) to Dec. 2025 (€1,402 Mil) but then declined from Dec. 2025 (€1,402 Mil) to Mar. 2026 (€760 Mil).

Solventum's annual Beginning Cash Position increased from Dec. 2023 (€56 Mil) to Dec. 2024 (€185 Mil) and increased from Dec. 2024 (€185 Mil) to Dec. 2025 (€651 Mil).

Solventum Beginning Cash Position Related Terms

Solventum Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Solventum's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solventum Beginning Cash Position Chart

Solventum Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 109.74 85.90 55.94 185.27 650.75

Solventum Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 700.23 465.58 420.89 1,402.27 760.34
STU:KB7
34GF Score
Solventum Corp STU:KB7
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solventum Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €760 Mil mean?
Solventum (STU:KB7) has a Beginning Cash Position of €760 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Solventum and its competitors.
Is Solventum's Beginning Cash Position too high?
Solventum's current Beginning Cash Position is €760 Mil. Overall, Solventum has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Solventum's Beginning Cash Position compare to COO and ALGN?
Solventum's Beginning Cash Position of €760 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Solventum and its competitors. Solventum's current Beginning Cash Position is €760 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solventum stock overvalued right now?
Solventum (STU:KB7) has a current Beginning Cash Position of €760 Mil. The current Beginning Cash Position is €760 Mil. Solventum's overall GF Score™ is 34/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Solventum (STU:KB7), the current Beginning Cash Position is €760 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solventum Business Description

Address 2510 Conway Avenue East, 3M Center, Building 275-6W, Maplewood, MN, USA, 55144
Solventum Corp is a healthcare company developing, manufacturing, and commercializing solutions leveraging material science, data science, and digital capabilities to address customer and patient needs. Its segments include MedSurg, which earns maximum revenue and provides wound therapy, I.V. site management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and OEM medical technologies; Dental Solutions, offering dental and orthodontic products such as brackets, restorative cements, and bonding agents; and Health Information Systems, providing software solutions including physician documentation, coding automation, speech recognition, and data visualization platforms. It operates in the United States, which earns the majority of revenue, and internationally.
34GF Score

Get the complete analysis for STU:KB7

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€71.20
Price